Navigation Links
Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
Date:4/5/2011

SAN FRANCISCO, April 5, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Pro-Pharmaceuticals, Inc. (OTCBB: PRWP) ("the Company") and raised its twelve month target price to $3.22. Ross Silver, Principal Analyst at Vista Partners stated, "The Company stated that it has reached an agreement with the FDA on the design of a pivotal, randomized, controlled, and blinded Phase III clinical trial of DAVANAT®. We believe this to be a significant milestone in the Company's history and could open the door for a potential partnership." Mr. Silver continued, "The Company has stated that it plans to initiate a Phase I/ll clinical trial of DAVANAT® in combination with a melanoma vaccine in collaboration with the Ludwig Institute in Brussels, Belgium in the third quarter.  This collaboration to date has shown that DAVANAT® activates tumor-specific cytotoxic T-cells allowing them to kill tumor cells. In addition, the Company plans to obtain an IND for treatment of liver fibrosis in the fourth quarter and plans to initiate clinical trials in early 2012."  Mr. Silver concludes, "We believe Pro-Pharmaceuticals to be one of the most attractive small cap biotechnology companies we have come across as a result of its robust clinical pipeline, which includes two candidates entering the clinic later this year and a late stage clinical candidate for metastatic colorectal cancer, all of which would compete in multi-billion dollar markets if approved. In addition, the Company has a strong management team, which is led by CEO Dr. Peter Traber, the former Chief Medical Officer of GlaxoSmithKline plc."

To download a FREE copy of the Pro-Pharmaceuticals, Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. Vista Partners LLC is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.

Contact:
877.215.4813 or info@vistapglobal.com


'/>"/>
SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harris Corporation Awarded Contract to Provide Engineering and Enterprise Support to Veteran Affairss VistA Imaging System
2. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
3. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
4. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
5. Vista Partners Updates Coverage on Raptor Pharmaceutical Corp.
6. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
7. Chula Vistas Dr. Peter Rullan Adds Alma Lasers Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients
8. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
9. New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)s Effect on Bone Quality in Osteoporotic Patients
10. Watson Confirms EVISTA(R) Patent Challenge
11. Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... CarpalAID is a revolutionary new product that relieves painful ... Carpal tunnel syndrome affects more than 8 million people a year. ... men. The common methods of treating CTS are painful surgery, the ... or gloves. ... CarpalAID is a clear patch worn on the palm of ...
(Date:7/11/2017)... 2017  The global market for liquid biopsy diagnostic ... million in 2016.  Although in early stages, the global ... particular as a result of the gradual shift towards ... introduction of a significant number of new liquid biopsy ... tumor biomarkers to guide treatment decisions. ...
(Date:7/10/2017)... , July 10, 2017  US medical equipment and ... 2021, according to Medical Equipment & Supplies: ... Freedonia Focus Reports. Continued increases in demand for medical ... of the population and supported by gains in disposable ... and supplies. New product introductions will also drive sales ...
Breaking Medicine Technology:
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... August 13-17 in National Harbor, MD. This year's theme focuses on the new ... principal benchmarks for quality and integrity in testing and calibration will be changed. ...
(Date:7/24/2017)... ... July 24, 2017 , ... A new report released today ... end-to-end sleep health care at scale, indicates record-breaking adherence results for the company’s ... positive airway pressure (PAP) therapy, the most widely utilized treatment for OSA, typically ...
(Date:7/24/2017)... ... July 24, 2017 , ... A Southern California-based author has ... sexual abuse, and how she has overcome them. “Forbidden Memories: A Memoir,” by author ... and how she has risen above. , In “Memories,” readers get a firsthand look ...
(Date:7/24/2017)... NEW CUMBERLAND, PA (PRWEB) , ... July 24, ... ... disability by 2030, today CURE announced that they have enrolled over 100,000 children ... with 158,000 afflicted children born every year in areas where treatment is limited ...
(Date:7/24/2017)... Falls Church, VA (PRWEB) , ... July 24, ... ... Auditors and Managers, **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 ... Assurance ends on Friday, July 28. , Increased FDA scrutiny and growing demands ...
Breaking Medicine News(10 mins):